Core Viewpoint - The company, 希玛医疗, has agreed to sell 55% of its subsidiary 阿波罗 to 明达眼镜, which will involve the cancellation of a debt of 504.9 million RMB, thereby relieving the company of all liabilities related to this debt [1] Group 1: Transaction Details - The transaction will result in 阿波罗 no longer being a non-wholly owned subsidiary of the company, and the company will not hold any equity interest in 阿波罗 post-transaction [1] - The deal price includes the cancellation and return of previously issued bonds worth 504.9 million RMB [1] Group 2: Strategic Initiatives - The company has implemented several strategic measures, focusing on ophthalmic services in Hong Kong and mainland China, as well as dental and medical services in Shenzhen [1] - The sale aligns with the company's strategy to optimize internal resource utilization [1]

Group 1 - The core point of the article is that Hema Medical (03309) has agreed to transfer 55% of Apollo's total issued share capital back to Mingda Glasses, which involves the cancellation of a debt of 504.9 million RMB [1] - The transaction will relieve the company of all liabilities under the aforementioned bond, indicating a strategic move to optimize internal resource utilization [1] - Following the completion of this transaction, Apollo will no longer be a non-wholly owned subsidiary of the company, and the company will not hold any equity interest in Apollo [1] Group 2 - The company is focusing on strategic initiatives, including enhancing ophthalmic services in Hong Kong and mainland China, as well as dental and medical services in Shenzhen [1] - The sale aligns with the company's strategy to optimize the use of internal resources [1]